Updated from 2:41 p.m. EDT
were among the worst-performing health-related stocks Monday, falling 10.5% after the company posted a wider second-quarter loss and announced the resignation of its chief executive.
The company posted a loss of $14.1 million, or 14 cents a share, on sales of $645,000. Results included a $7.2 million charge related to the company's acquisition of additional rights to Neurodex. Analysts polled by Thomson First Call were expecting a loss of 8 cents a share. A year ago, the company reported a loss of $6.7 million, or 9 cents a share, on sales of $856,000.
Separately, Avanir announced that Gerald Yakatan resigned as CEO, effective immediately. After his resignation, Yakatan will serve as a consultant for one year, advising the company on its Neurodex new drug application. Charles Mathews, the company's chairman, will assist management on day-to-day operational matters until a permanent CEO is found. Shares traded down 29 cents to $2.48.
rose 11.1% after the pet pharmacy company posted fourth-quarter earnings that were better than expected. The company earned $2.4 million, or 10 cents a share, on sales of $23.5 million. Analysts were expecting earnings of 7 cents a share on sales of $23.8 million. A year ago, the company earned $1.3 million, or 6 cents a share, on sales of $21.5 million. Shares traded up 72 cents to $7.22.
Dialysis Corp. of America
( DCAI) rose 0.5% after the company posted a 23% increase in first-quarter sales on a double-digit increase in earnings. The company, which manages freestanding kidney hemodialysis centers, earned $324,000, or 4 cents a share, on sales of $10.6 million. A year ago, the company earned $288,000, or 3 cents a share, on sales of $8.6 million. Shares traded up 9 cents to $17.60.
( BIVN) traded actively after the company posted a third-quarter loss that was narrower than expected. The company reported a loss of $2.9 million, or 8 cents a share, on sales of $1.4 million. Analysts were expecting a loss of 12 cents a share on sales of $1.24 million. A year ago, the company posted a loss of $4.1 million, or 21 cents a share, on sales of $850,000. Shares traded down 11 cents to $6.77.
Other health-care volume movers included
, up 37 cents to $28.23;
, down $4.56 to $27.29;
, down 4 cents to $7.22;
, up $1.65 to $38.65;
, up 87 cents to $62.99;
( DNA), up $1.07 to $73.77;
, down 1 cent to $33.45;
, down 7 cents to $3.48;
Johnson & Johnson
, up 54 cents to $67.64;
, up 16 cents to $25.46; and
( SGP), up 10 cents to $20.35.